



Solution

VIRO AI is a computational virology and bioinformatics-driven platform that leverages artificial intelligence, molecular modeling, and evolutionary algorithms to proactively predict viral mutations, simulate protein-ligand interactions, generate antidotes, and provide outbreak-prevention strategies in real time.

1. Predictive Viral Mutation Modeling

- VIRO AI applies genomic sequence alignment algorithms and phylogenetic tree reconstruction (Maximum Likelihood, Bayesian Inference) to predict probable mutation pathways in viral genomes.
- Through genetic algorithms (GA) and Markov Chain Monte Carlo (MCMC) simulations, the system forecasts amino acid substitutions, insertions, and deletions that could alter viral protein structures.
- This allows early identification of escape mutations responsible for immune evasion and drug resistance.

2. Protein Structure Prediction and Folding Simulation

- VIRO AI integrates AI-based protein folding models with molecular dynamics (MD) simulations using CHARMM, AMBER, and GROMOS force fields.
- Proteins are analyzed through ΔG (Gibbs free energy change), RMSD (root-mean-square deviation), RMSF (root mean square fluctuation), and solvent-accessible surface area (SASA).
- Outputs include stable conformational states, epitope exposure, and potential binding pockets for therapeutic targeting.

3. AI-Driven Antidote and Drug Candidate Generation

- Uses deep generative models (VAE, GANs) to design novel inhibitors, antibodies, and peptide antivirals.
- Employs molecular docking (AutoDock, Glide) and free energy binding predictions (MM-PBSA/MM-GBSA).
- Generates a drug candidate pipeline ranked by binding energy, ADME-Tox predictions, and thermodynamic stability.

4. Prediction of Deadliness Score

- VIRO AI computes a “Pathogenicity & Deadliness Score” using:
 - Viral replication rate (R_0) from epidemiological models.
 - Binding affinity to host receptors (Kd values).
 - Cytopathic effect (CPE) index from protein–cell interaction simulations.
 - Predicted immune evasion potential using epitope masking simulations.
- This score allows classification of mutation severity and early prioritization of high-risk strains.

5. In-Silico Clinical Trial Simulation

- Uses digital twin models of human physiology to test drug candidates virtually.
- Simulates toxicity pathways, cytokine storms, allergic reactions, and metabolic effects.
- Greatly reduces human life loss and unpredicted side effects in clinical testing phases.

6. Symptoms and Preventive Measures Prediction

- Maps predicted viral protein–host receptor interactions to known clinical pathways.
- Uses knowledge graph AI trained on biomedical ontologies (UMLS, MeSH, SNOMED CT) to correlate mutations with symptom clusters (respiratory, neurological, gastrointestinal).
- Suggests preventive measures (vaccination updates, PPE requirements, antiviral prophylaxis, lifestyle interventions) based on predicted severity.

7. Chemical Modifications in Best-Performing Drugs

- VIRO AI applies quantum mechanics/molecular mechanics (QM/MM) hybrid simulations to test structural analogues of lead compounds.
- Suggests chemical modifications (hydroxylation, methylation, halogenation) to improve:
 - Binding affinity (ΔG improvement)
 - Bioavailability
 - Reduced toxicity
- Ensures continuous optimization of top-performing candidates as new mutations emerge.

8. Real-Time Outbreak Forecasting and Early Warning System

- Connects with global genomic surveillance databases (GISAID, NCBI Virus, WHO’s Athina API).

- Uses stochastic SEIR models with mutation-adjusted R_0 for outbreak curve forecasting.
- Provides government dashboards with early alerts and intervention strategies.

9. 3D Molecular Visualization

- Provides real-time interactive 3D visualization of:
 - Viral proteins (mutated vs. original structure)
 - Antidote/drug binding conformations
 - Virus–host receptor interactions (e.g., Spike–ACE2 docking)
- Built using WebGL + GPU-accelerated rendering for researchers, with export in PDB, MOL2, CIF formats for lab use.

10. Scalability and Cloud-Based Accessibility

- Operates on GPU-accelerated distributed cloud systems for high-throughput protein simulations.
- Provides API-based integration for pharma companies, governments, and research labs.
- Democratizes access to predictive virology tools for low-resource settings.

11. End-to-End Translational Pipeline

- Input: Viral genome/protein data (FASTA, PDB).
- Processing: Mutation prediction → Folding simulation → Deadliness score → Antidote design → Clinical trial simulation → Outbreak forecast.
- Output: Ranked mutation risks, antidote candidates with modifications, predicted symptoms, preventive measures, and 3D molecular visualization.